Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

Bartsch, 1979, Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia, J Urol, 122, 487, 10.1016/S0022-5347(17)56476-9

Shapiro, 1992, The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle, Prostate, 22, 297, 10.1002/pros.2990210406

Boyle, 1991, Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed, Eur Urol, 20, 3, 10.1159/000471738

Sagnier, 1996, International comparison of the community prevalence of symptoms of prostatism in four countries, Eur Urol, 29, 15, 10.1159/000473711

Boyle, 1996, Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph, J Urol, 155, 176, 10.1016/S0022-5347(01)66587-X

McConnell, 1991, The pathophysiology of benign prostatic hyperplasia, J Androl, 12, 356, 10.1002/j.1939-4640.1991.tb00272.x

Walsh, 1983, Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal, J Clin Invest, 72, 1772, 10.1172/JCI111137

Wilkin, 1979, Stromal localization of testosterone 5α-reductase in normal, hyperplastic and carcinomatous prostates, 20, 419

Brooks, 1982, A new class of A4-5α-reductase inhibitors, Arch Andrology, 9, 56

Gormley, 1992, The effect of finasteride in men with benign prostatic hyperplasia., N Engl J Med, 327, 1185, 10.1056/NEJM199210223271701

1993, Finasteride (MK-906) in the treatment of benign prostatic hyperplasia, Prostate, 22, 291, 10.1002/pros.2990220403

Andersen, 1995, Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebo-con-trolled study, Urology, 46, 631, 10.1016/S0090-4295(99)80291-X

Beisland, 1992, Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia, Eur Urol, 22, 271, 10.1159/000474771

Stoner, 1994, Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia, Urology, 43, 284, 10.1016/0090-4295(94)90068-X

Lepor, 1996, J Urol, 155, 587A, 10.1016/S0022-5347(01)66633-3

Cockett, 1993, Recommendations of the International Consensus Committee, 553

McConnell, 1994, Benign prostatic hyperplasia; diagnosis and treatment

Rahmouni, 1992, Ac-curacy of in-vivo assessment of prostate volume by MRI and transrectal ultrasonography, J Comput Assist Tomogr, 16, 935, 10.1097/00004728-199211000-00020

Al-Rimawi, 1994, Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostate volume, Br J Urol, 74, 596, 10.1111/j.1464-410X.1994.tb09190.x

Hricak, 1987, Evaluation of prostate size: a comparison of ultrasound and magentic resonance imaging, Urol Radiol, 9, 1, 10.1007/BF02932619

Maritz, 1989

Rosenberg, 1973, Linear regression with randomly dispersed parameters, Biometrika, 60, 65, 10.1093/biomet/60.1.65

Strenio, 1983, Empirical Bayes estimation of individual growth-curve parameters and their relationship to covariates, Biometrics, 39, 71, 10.2307/2530808

Morris, 1983, Parametric Empirical Bayes inference: theory and applications, J Am Stat Assoc, 78, 47, 10.2307/2287098

Raudenbush, 1985, Empirical Bayes meta-analysis, J Educational Behavioral Statistics, 10, 75, 10.3102/10769986010002075

Lepor, 1995, Long-term results of medical therapies for BPH, Curr Opin Urol, 5, 18, 10.1097/00042307-199501000-00005

Barry, 1995, Benign prostatic hyperplasia-specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?, J Urol, 154, 1770, 10.1016/S0022-5347(01)66780-6

Barry, 1993, Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia, J Urol, 150, 351, 10.1016/S0022-5347(17)35482-4

Girman, 1996, Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate, J Urol, 153, 1510, 10.1016/S0022-5347(01)67448-2

Roehrborn, 1986, The role of transabdominal ultrasound in the preoperative evaluation of patients with benign prostatic hypertrophy, J Urol, 135, 1190, 10.1016/S0022-5347(17)46032-0

Oesterling, 1993, Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges, JAMA, 270, 860, 10.1001/jama.270.7.860

Abrams, 1994, New words for old: lower urinary tract symptoms for “prostatism, ” BMJ, 308, 929, 10.1136/bmj.308.6934.929

Boyarski, 1976, A new look at bladder neck obstruction by the Food and Drug Ad-ministration regulators: guide lines for investigation of benign prostatic hypertrophy, Trans Am Assoc Genitourin Surg, 68, 29

Bolognese, 1992, Validation of a symptoms questionnaire for benign prostatic hyperplasia, Prostate, 21, 247, 10.1002/pros.2990210308

Barry, 1992, The American Urological Association symptom index for benign prostatic hyperplasia, J Urol, 148, 1549, 10.1016/S0022-5347(17)36966-5